Richard A Becker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11828000/publications.pdf

Version: 2024-02-01

53 papers	1,819 citations	236925 25 h-index	276875 41 g-index
54 all docs	54 docs citations	54 times ranked	1866 citing authors

#	Article	IF	Citations
1	Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence. Regulatory Toxicology and Pharmacology, 2015, 72, 514-537.	2.7	198
2	Alternative methods of selecting rat hepatocellular noduli resistant to 2-acetylaminofluorene. International Journal of Cancer, 1987, 40, 643-645.	5.1	93
3	Read-across approaches - misconceptions, promises and challenges ahead. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 387-396.	1.5	90
4	Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. Regulatory Toxicology and Pharmacology, 2015, 71, 463-477.	2.7	87
5	A survey of frameworks for best practices in weight-of-evidence analyses. Critical Reviews in Toxicology, 2013, 43, 753-784.	3.9	83
6	Toward the Development and Application of an Environmental Risk Assessment Framework for Microplastic. Environmental Toxicology and Chemistry, 2019, 38, 2087-2100.	4.3	69
7	Methylation of liver DNA guanine in hydrazine hepatotoxicity: dose-response and kinetic characteristics of O6-methylguanine and formation and persistence in rats. Carcinogenesis, 1981, 2, 1181-1188.	2.8	67
8	Evaluation of EPAâ€™s Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results. Regulatory Toxicology and Pharmacology, 2011, 59, 397-411.	2.7	58
9	Hypothesis-driven weight of evidence framework for evaluating data within the US EPAâ€™s Endocrine Disruptor Screening Program. Regulatory Toxicology and Pharmacology, 2011, 61, 185-191.	2.7	58
10	Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review. Environment International, 2016, 92-93, 630-646.	10.0	58
11	Validation of an in vivo developmental toxicity screen in the mouse. Teratogenesis, Carcinogenesis, and Mutagenesis, 1986, 6, 361-374.	0.8	54
12	Utilizing Threshold of Toxicological Concern (TTC) with high throughput exposure predictions (HTE) as a risk-based prioritization approach for thousands of chemicals. Computational Toxicology, 2018, 7, 58-67.	3.3	53
13	Quantitative weight of evidence to assess confidence in potential modes of action. Regulatory Toxicology and Pharmacology, 2017, 86, 205-220.	2.7	50
14	Toxicity Testing in the 21st Century: A View from the Chemical Industry. Toxicological Sciences, 2009, 112, 297-302.	3.1	48
15	An exposure:activity profiling method for interpreting high-throughput screening data for estrogenic activityâ€”Proof of concept. Regulatory Toxicology and Pharmacology, 2015, 71, 398-408.	2.7	45
16	Advancing human health risk assessment: Integrating recent advisory committee recommendations. Critical Reviews in Toxicology, 2013, 43, 467-492.	3.9	42
17	The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor. Regulatory Toxicology and Pharmacology, 2015, 73, 172-190.	2.7	42
18	Evidence-based toxicology for the 21st century: Opportunities and challenges. ALTEX: Alternatives To Animal Experimentation, 2013, 30, 74-104.	1.5	42

#	Article	IF	Citations
19	How well can carcinogenicity be predicted by high throughput â€œcharacteristics of carcinogensâ€• mechanistic data?. Regulatory Toxicology and Pharmacology, 2017, 90, 185-196.	2.7	37
20	Relevance Weighting of Tier 1 Endocrine Screening Endpoints by Rank Order. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2014, 101, 90-113.	1.4	36
21	A summary of the results of 55 chemicals screened for developmental toxicity in mice. Teratogenesis, Carcinogenesis, and Mutagenesis, 1987, 7, 17-28.	0.8	35
22	Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regulatory Toxicology and Pharmacology, 2013, 65, 259-268.	2.7	35
23	Developing context appropriate toxicity testing approaches using new alternative methods (NAMs). ALTEX: Alternatives To Animal Experimentation, 2019, 36, 532-534.	1.5	30
24	Good Laboratory Practices and Safety Assessments. Environmental Health Perspectives, 2009, 117, A482-3; author reply A483-4.	6.0	29
25	Developing scientific confidence in HTS-derived prediction models: Lessons learned from an endocrine case study. Regulatory Toxicology and Pharmacology, 2014, 69, 443-450.	2.7	27
26	Approaches for describing and communicating overall uncertainty in toxicity characterizations: U.S. Environmental Protection Agency's Integrated Risk Information System (IRIS) as a case study. Environment International, 2016, 89-90, 110-128.	10.0	27
27	Enhancing Credibility of Chemical Safety Studies: Emerging Consensus on Key Assessment Criteria. Environmental Health Perspectives, 2011, 119, 757-764.	6.0	26
28	Report of an ISRTP Workshop: Progress and barriers to incorporating alternative toxicological methods in the U.S.. Regulatory Toxicology and Pharmacology, 2006, 46, 18-22.	2.7	24
29	Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action. Critical Reviews in Toxicology, 2018, 48, 312-337.	3.9	23
30	FutureTox III: Bridges for Translation. Toxicological Sciences, 2017, 155, 22-31.	3.1	22
31	Lessons learned, challenges, and opportunities: The U.S. Endocrine Disruptor Screening Program. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 63-78.	1.5	22
32	Tiered toxicity testing: Evaluation of toxicity-based decision triggers for human health hazard characterization. Food and Chemical Toxicology, 2007, 45, 2454-2469.	3.6	20
33	Modernizing problem formulation for risk assessment necessitates articulation of mode of action. Regulatory Toxicology and Pharmacology, 2015, 72, 538-551.	2.7	19
34	Does GLP enhance the quality of toxicological evidence for regulatory decisions?: TABLE 1.. Toxicological Sciences, 2016, 151, 206-213.	3.1	17
35	Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium. Toxicological Sciences, 2022, 188, 143-152.	3.1	17
36	How well can inÂvitro data predict inÂvivo effects of chemicals? Rodent carcinogenicity as a case study. Regulatory Toxicology and Pharmacology, 2016, 77, 54-64.	2.7	16

#	Article	IF	Citations
37	An enhanced tiered toxicity testing framework with triggers for assessing hazards and risks of commodity chemicals. Regulatory Toxicology and Pharmacology, 2010, 58, 382-394.	2.7	15
38	Overview and summary: Workshop on the Chernoff/Kavlock preliminary developmental toxicity test. Teratogenesis, Carcinogenesis, and Mutagenesis, 1987, 7, 119-127.	0.8	14
39	Recommendations for further revisions to improve the International Agency for Research on Cancer (IARC) Monograph program. Regulatory Toxicology and Pharmacology, 2020, 113, 104639.	2.7	13
40	Development of Screening Tools for the Interpretation of Chemical Biomonitoring Data. Journal of Toxicology, 2012, 2012, 1-10.	3.0	11
41	The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay. Toxicology and Applied Pharmacology, 2020, 387, 114774.	2.8	10
42	Assessment of margin of exposure based on biomarkers in blood: An exploratory analysis. Regulatory Toxicology and Pharmacology, 2011, 61, 44-52.	2.7	9
43	Challenges in using the ToxRefDB as a resource for toxicity prediction modeling. Regulatory Toxicology and Pharmacology, 2015, 72, 610-614.	2.7	8
44	Results of the negative control chemical allyl alcohol in the 15â€day intact adult male rat screening assay for endocrine activity. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2008, 83, 117-122.	1.4	6
45	Interpreting Estrogen Screening Assays in the Context of Potency and Human Exposure Relative to Natural Exposures to Phytoestrogens. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2014, 101, 114-124.	1.4	6
46	Chemical Safety Studies: Conrad and Becker Respond. Environmental Health Perspectives, 2011, 119, .	6.0	5
47	Internal Threshold of Toxicological Concern (iTTC): Where We Are Today and What Is Possible in the Near Future. Frontiers in Toxicology, 2020, 2, 621541.	3.1	5
48	Good Laboratory Practices: Becker et al. Respond. Environmental Health Perspectives, 2010, 118, .	6.0	4
49	Transforming regulatory safety evaluations using New Approach Methodologies: A perspective of an industrial toxicologist. Current Opinion in Toxicology, 2019, 15, 93-98.	5.0	2
50	Interlaboratory Study Comparison of the 15â€Day Intact Adult Male Rat Screening Assay: Evaluation of an Antithyroid Chemical and a Negative Control Chemical. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2012, 95, 63-78.	1.4	1
51	Instruments for Assessing Risk of Bias and Other Methodological Criteria of Animal Studies: Omission of Well-Established Methods. Environmental Health Perspectives, 2014, 122, A66-7.	6.0	1
52	Does The Standard Toxicological Testing Paradigm for Industrial Chemicals Apply to Screening for Children's Health Risks?. The Open Toxicology Journal, 2008, 2, 42-60.	1.0	1
53	The Predictive Analytics Toolkit (PAT): User-friendly predictive analytics for advancing new approach methodologies (NAMs). Computational Toxicology, 2019, 12, 100107.	3.3	0